Nefazodone

Hispanic patients with major depressive disorder seem to have similar response rates compared to other nefazodone trials with non-Hispanic patients. Fifty-eight percent of the full in-tent-to-treat sample were rated as responders at the end of the 8-week trial.
A higher drop-out rate was found compared to previous trials with predominantly non-Hispanic White subjects using nefazodone (42 % versus 21-33%). The authors did not find evidence that supports the need for lower doses of nefazodone among Hispanics (no elevated side effect reports, no lower mean endpoint doses, nor any reduction in the overall efficacy).
(N = 50, open trial with Spanish-speaking outpatients composed of Latin American migrants to the U.S., New York City), Sanchez-Lacay et al., 2001.